开云app官网登录入口网页版-官方正版

#激素受体阳性#

54篇内容 | 1537人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1980882, encodeId=866a1980882c2, content=<a href='/topic/show?id=aaf6668192d' target=_blank style='color:#2F92EE;'>#激素受体阳性#</a>, objectTitle=2022年第6届国际晚期乳腺癌共识会议对激素受体阳性晚期乳腺癌的更新要点及解读, objectType=article, longId=732887, objectId=3c45e3288756, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3c45e3288756, replyNumber=0, likeNumber=60, createdTime=2023-04-09, rootId=0, userName=mjldent, userId=5662228, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3c45e3288756, moduleTitle=2022年第6届国际晚期乳腺癌共识会议对激素受体阳性晚期乳腺癌的更新要点及解读, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=3c45e3288756)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1980879, encodeId=d07419808e9aa, content=<a href='/topic/show?id=aaf6668192d' target=_blank style='color:#2F92EE;'>#激素受体阳性#</a>, objectTitle=Nat Med：Dalpiciclib联合氟维司群治疗激素受体阳性和HER2阴性晚期乳腺癌疗效分析, objectType=article, longId=219832, objectId=9405219832ba, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9405219832ba, replyNumber=0, likeNumber=71, createdTime=2022-07-16, rootId=0, userName=mjldent, userId=5662228, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9405219832ba, moduleTitle=Nat Med：Dalpiciclib联合氟维司群治疗激素受体阳性和HER2阴性晚期乳腺癌疗效分析, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=9405219832ba)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1980880, encodeId=ad82198088084, content=<a href='/topic/show?id=aaf6668192d' target=_blank style='color:#2F92EE;'>#激素受体阳性#</a>, objectTitle=JAMA Oncol：Vistusertib联合阿那曲唑治疗激素受体阳性子宫内膜癌, objectType=article, longId=727038, objectId=8cb4e270380d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8cb4e270380d, replyNumber=0, likeNumber=60, createdTime=2022-07-10, rootId=0, userName=mjldent, userId=5662228, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8cb4e270380d, moduleTitle=JAMA Oncol：Vistusertib联合阿那曲唑治疗激素受体阳性子宫内膜癌, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=8cb4e270380d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1980881, encodeId=48c11980881cd, content=<a href='/topic/show?id=aaf6668192d' target=_blank style='color:#2F92EE;'>#激素受体阳性#</a>, objectTitle=【最后一课】张剑教授：肿瘤3天训练营丨激素受体阳性晚期乳腺癌的治疗更新, objectType=article, longId=728862, objectId=d4ebe2886200, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d4ebe2886200, replyNumber=0, likeNumber=62, createdTime=2022-12-12, rootId=0, userName=mjldent, userId=5662228, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d4ebe2886200, moduleTitle=【最后一课】张剑教授：肿瘤3天训练营丨激素受体阳性晚期乳腺癌的治疗更新, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=d4ebe2886200)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1980875, encodeId=40af19808e55c, content=<a href='/topic/show?id=aaf6668192d' target=_blank style='color:#2F92EE;'>#激素受体阳性#</a>, objectTitle=Breast：HER2低表达对激素受体阳性早期乳腺癌预后的影响, objectType=article, longId=217172, objectId=1d3d21e17209, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1d3d21e17209, replyNumber=0, likeNumber=138, createdTime=2022-04-26, rootId=0, userName=mjldent, userId=5662228, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1d3d21e17209, moduleTitle=Breast：HER2低表达对激素受体阳性早期乳腺癌预后的影响, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=1d3d21e17209)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1980877, encodeId=c07119808e726, content=<a href='/topic/show?id=aaf6668192d' target=_blank style='color:#2F92EE;'>#激素受体阳性#</a>, objectTitle=JAMA Oncol：对于激素受体阳性乳腺癌，帕博西尼 ➕来曲唑优于帕博西尼 ➕氟维司群, objectType=article, longId=218872, objectId=63df2188e27d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=63df2188e27d, replyNumber=0, likeNumber=87, createdTime=2022-08-06, rootId=0, userName=mjldent, userId=5662228, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=63df2188e27d, moduleTitle=JAMA Oncol：对于激素受体阳性乳腺癌，帕博西尼 ➕来曲唑优于帕博西尼 ➕氟维司群, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=63df2188e27d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1980876, encodeId=b39619808e63a, content=<a href='/topic/show?id=aaf6668192d' target=_blank style='color:#2F92EE;'>#激素受体阳性#</a>, objectTitle=Clin Cancer Res：高 sTK1 水平提示内分泌治疗的激素受体阳性转移性乳腺癌患者的预后不良, objectType=article, longId=217354, objectId=6dd121e3540c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6dd121e3540c, replyNumber=0, likeNumber=80, createdTime=2021-12-31, rootId=0, userName=mjldent, userId=5662228, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6dd121e3540c, moduleTitle=Clin Cancer Res：高 sTK1 水平提示内分泌治疗的激素受体阳性转移性乳腺癌患者的预后不良, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=6dd121e3540c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1980878, encodeId=fd7019808e8f7, content=<a href='/topic/show?id=aaf6668192d' target=_blank style='color:#2F92EE;'>#激素受体阳性#</a>, objectTitle=Lancet Oncol：CDKI联合氟维司群有望成为激素受体阳性、HER2阴性的晚期乳腺癌的标准治疗方案！, objectType=article, longId=219161, objectId=aee8219161b7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=aee8219161b7, replyNumber=0, likeNumber=81, createdTime=2021-12-22, rootId=0, userName=mjldent, userId=5662228, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=aee8219161b7, moduleTitle=Lancet Oncol：CDKI联合氟维司群有望成为激素受体阳性、HER2阴性的晚期乳腺癌的标准治疗方案！, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=aee8219161b7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1980874, encodeId=bc2a19808e492, content=<a href='/topic/show?id=aaf6668192d' target=_blank style='color:#2F92EE;'>#激素受体阳性#</a>, objectTitle=Br J Cancer：CYP3A7 rs45446698 SNP：绝经前的雌酮和孕酮水平与激素受体阳性乳腺癌患病风险的相关因素, objectType=article, longId=206635, objectId=92752066358b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=92752066358b, replyNumber=0, likeNumber=124, createdTime=2021-08-07, rootId=0, userName=mjldent, userId=5662228, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=92752066358b, moduleTitle=Br J Cancer：CYP3A7 rs45446698 SNP：绝经前的雌酮和孕酮水平与激素受体阳性乳腺癌患病风险的相关因素, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=92752066358b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1980873, encodeId=b75019808e39b, content=<a href='/topic/show?id=aaf6668192d' target=_blank style='color:#2F92EE;'>#激素受体阳性#</a>, objectTitle=Nat Med：雄激素受体：雌激素受体阳性乳腺癌的抑癌因子, objectType=article, longId=206021, objectId=4df820602190, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4df820602190, replyNumber=0, likeNumber=93, createdTime=2021-11-08, rootId=0, userName=mjldent, userId=5662228, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4df820602190, moduleTitle=Nat Med：雄激素受体：雌激素受体阳性乳腺癌的抑癌因子, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=4df820602190)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1980872, encodeId=e23d19808e268, content=<a href='/topic/show?id=aaf6668192d' target=_blank style='color:#2F92EE;'>#激素受体阳性#</a>, objectTitle=Clin Cancer Res：早期激素受体阳性乳腺癌患者的BRCAness和肿瘤炎症基因表达特征, objectType=article, longId=201647, objectId=842c20164e18, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=842c20164e18, replyNumber=0, likeNumber=86, createdTime=2021-07-12, rootId=0, userName=mjldent, userId=5662228, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=842c20164e18, moduleTitle=Clin Cancer Res：早期激素受体阳性乳腺癌患者的BRCAness和肿瘤炎症基因表达特征, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=842c20164e18)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1980869, encodeId=5737198086907, content=<a href='/topic/show?id=aaf6668192d' target=_blank style='color:#2F92EE;'>#激素受体阳性#</a>, objectTitle=全方位、全周期管理—孙蔚莉教授谈激素受体阳性乳腺癌患者全程管理, objectType=article, longId=192619, objectId=b93b1926195e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b93b1926195e, replyNumber=0, likeNumber=0, createdTime=2020-11-23, rootId=0, userName=mjldent, userId=5662228, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b93b1926195e, moduleTitle=全方位、全周期管理—孙蔚莉教授谈激素受体阳性乳腺癌患者全程管理, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=b93b1926195e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1980863, encodeId=cfc119808630b, content=<a href='/topic/show?id=aaf6668192d' target=_blank style='color:#2F92EE;'>#激素受体阳性#</a>, objectTitle=多中心临床试验成果给激素受体阳性乳腺癌更多临床选择, objectType=article, longId=181067, objectId=57cc18106e37, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=57cc18106e37, replyNumber=0, likeNumber=70, createdTime=2020-06-21, rootId=0, userName=mjldent, userId=5662228, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=57cc18106e37, moduleTitle=多中心临床试验成果给激素受体阳性乳腺癌更多临床选择, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=57cc18106e37)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1980864, encodeId=b06a1980864e9, content=<a href='/topic/show?id=aaf6668192d' target=_blank style='color:#2F92EE;'>#激素受体阳性#</a>, objectTitle=年轻绝经前激素受体阳性晚期乳腺癌的诊疗思考, objectType=article, longId=181110, objectId=2c67181110f2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2c67181110f2, replyNumber=0, likeNumber=75, createdTime=2020-04-15, rootId=0, userName=mjldent, userId=5662228, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2c67181110f2, moduleTitle=年轻绝经前激素受体阳性晚期乳腺癌的诊疗思考, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=2c67181110f2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1980871, encodeId=c4f719808e1e5, content=<a href='/topic/show?id=aaf6668192d' target=_blank style='color:#2F92EE;'>#激素受体阳性#</a>, objectTitle=Breast Cancer Res Treat：Palbociclib加来曲唑作为雌激素受体阳性/人表皮生长因子受体2阴性晚期乳腺癌的一线治疗效果, objectType=article, longId=195894, objectId=347c195894a4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=347c195894a4, replyNumber=0, likeNumber=74, createdTime=2021-03-30, rootId=0, userName=mjldent, userId=5662228, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=347c195894a4, moduleTitle=Breast Cancer Res Treat：Palbociclib加来曲唑作为雌激素受体阳性/人表皮生长因子受体2阴性晚期乳腺癌的一线治疗效果, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=347c195894a4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1980861, encodeId=436c19808611f, content=<a href='/topic/show?id=aaf6668192d' target=_blank style='color:#2F92EE;'>#激素受体阳性#</a>, objectTitle=靶向联合一线治疗激素受体阳性晚期乳腺癌, objectType=article, longId=177120, objectId=26741e7120e8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=26741e7120e8, replyNumber=0, likeNumber=82, createdTime=2019-08-28, rootId=0, userName=mjldent, userId=5662228, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=26741e7120e8, moduleTitle=靶向联合一线治疗激素受体阳性晚期乳腺癌, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=26741e7120e8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1980868, encodeId=c281198086813, content=<a href='/topic/show?id=aaf6668192d' target=_blank style='color:#2F92EE;'>#激素受体阳性#</a>, objectTitle=Lancet Oncol：CD4/6抑制剂用于激素受体阳性、HER2阴性转移性乳腺癌, objectType=article, longId=184893, objectId=50041848939a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=50041848939a, replyNumber=0, likeNumber=72, createdTime=2020-01-24, rootId=0, userName=mjldent, userId=5662228, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=50041848939a, moduleTitle=Lancet Oncol：CD4/6抑制剂用于激素受体阳性、HER2阴性转移性乳腺癌, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=50041848939a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1980860, encodeId=00261980860df, content=<a href='/topic/show?id=aaf6668192d' target=_blank style='color:#2F92EE;'>#激素受体阳性#</a>, objectTitle=Knight Therapeutics的Neratinib成为第一个在加拿大获批的抗HER2疗法，用于激素受体阳性、HER2阳性早期乳腺癌的延长辅助治疗, objectType=article, longId=175669, objectId=17911e5669f5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=17911e5669f5, replyNumber=0, likeNumber=76, createdTime=2020-03-12, rootId=0, userName=mjldent, userId=5662228, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=17911e5669f5, moduleTitle=Knight Therapeutics的Neratinib成为第一个在加拿大获批的抗HER2疗法，用于激素受体阳性、HER2阳性早期乳腺癌的延长辅助治疗, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=17911e5669f5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1980870, encodeId=1f6519808e098, content=<a href='/topic/show?id=aaf6668192d' target=_blank style='color:#2F92EE;'>#激素受体阳性#</a>, objectTitle=Cancer Med：二氯化镭-223联合激素治疗激素受体阳性骨转移性乳腺癌的II期研究, objectType=article, longId=192853, objectId=22aa1928533a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=22aa1928533a, replyNumber=0, likeNumber=78, createdTime=2021-01-14, rootId=0, userName=mjldent, userId=5662228, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=22aa1928533a, moduleTitle=Cancer Med：二氯化镭-223联合激素治疗激素受体阳性骨转移性乳腺癌的II期研究, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=22aa1928533a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1980862, encodeId=1333198086214, content=<a href='/topic/show?id=aaf6668192d' target=_blank style='color:#2F92EE;'>#激素受体阳性#</a>, objectTitle=让激素受体阳性乳腺癌患者的选择不再困难, objectType=article, longId=178554, objectId=abd51e85543b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=abd51e85543b, replyNumber=0, likeNumber=0, createdTime=2019-09-06, rootId=0, userName=mjldent, userId=5662228, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=abd51e85543b, moduleTitle=让激素受体阳性乳腺癌患者的选择不再困难, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=abd51e85543b)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 风湿免疫小助手

激素受体阳性

2020-05-29

mjldent (审核中...)

前往app查看评论内容

#激素受体阳性#

2022年第6届国际晚期乳腺癌共识会议对激素受体阳性晚期乳腺癌的更新要点及解读

2023-04-09

mjldent (审核中...)

前往app查看评论内容

#激素受体阳性#

Nat Med：Dalpiciclib联合氟维司群治疗激素受体阳性和HER2阴性晚期乳腺癌疗效分析

2022-07-16

mjldent (审核中...)

前往app查看评论内容

#激素受体阳性#

JAMA Oncol：Vistusertib联合阿那曲唑治疗激素受体阳性子宫内膜癌

2022-07-10

mjldent (审核中...)

前往app查看评论内容

#激素受体阳性#

【最后一课】张剑教授：肿瘤3天训练营丨激素受体阳性晚期乳腺癌的治疗更新

2022-12-12

mjldent (审核中...)

前往app查看评论内容

#激素受体阳性#

Breast：HER2低表达对激素受体阳性早期乳腺癌预后的影响

2022-04-26

mjldent (审核中...)

前往app查看评论内容

#激素受体阳性#

JAMA Oncol：对于激素受体阳性乳腺癌，帕博西尼 ➕来曲唑优于帕博西尼 ➕氟维司群

2022-08-06

mjldent (审核中...)

前往app查看评论内容

#激素受体阳性#

Clin Cancer Res：高 sTK1 水平提示内分泌治疗的激素受体阳性转移性乳腺癌患者的预后不良

2021-12-31

mjldent (审核中...)

前往app查看评论内容

#激素受体阳性#

Lancet Oncol：CDKI联合氟维司群有望成为激素受体阳性、HER2阴性的晚期乳腺癌的标准治疗方案！

2021-12-22

mjldent (审核中...)

前往app查看评论内容

#激素受体阳性#

Br J Cancer：CYP3A7 rs45446698 SNP：绝经前的雌酮和孕酮水平与激素受体阳性乳腺癌患病风险的相关因素

2021-08-07

mjldent (审核中...)

前往app查看评论内容

#激素受体阳性#

Nat Med：雄激素受体：雌激素受体阳性乳腺癌的抑癌因子

2021-11-08

mjldent (审核中...)

前往app查看评论内容

#激素受体阳性#

Clin Cancer Res：早期激素受体阳性乳腺癌患者的BRCAness和肿瘤炎症基因表达特征

2021-07-12

mjldent (审核中...)

前往app查看评论内容

#激素受体阳性#

全方位、全周期管理—孙蔚莉教授谈激素受体阳性乳腺癌患者全程管理

2020-11-23

mjldent (审核中...)

前往app查看评论内容

#激素受体阳性#

多中心临床试验成果给激素受体阳性乳腺癌更多临床选择

2020-06-21

mjldent (审核中...)

前往app查看评论内容

#激素受体阳性#

年轻绝经前激素受体阳性晚期乳腺癌的诊疗思考

2020-04-15

mjldent (审核中...)

前往app查看评论内容

#激素受体阳性#

Breast Cancer Res Treat：Palbociclib加来曲唑作为雌激素受体阳性/人表皮生长因子受体2阴性晚期乳腺癌的一线治疗效果

2021-03-30

mjldent (审核中...)

前往app查看评论内容

#激素受体阳性#

靶向联合一线治疗激素受体阳性晚期乳腺癌

2019-08-28

mjldent (审核中...)

前往app查看评论内容

#激素受体阳性#

Lancet Oncol：CD4/6抑制剂用于激素受体阳性、HER2阴性转移性乳腺癌

2020-01-24

mjldent (审核中...)

前往app查看评论内容

#激素受体阳性#

Knight Therapeutics的Neratinib成为第一个在加拿大获批的抗HER2疗法，用于激素受体阳性、HER2阳性早期乳腺癌的延长辅助治疗

2020-03-12

mjldent (审核中...)

前往app查看评论内容

#激素受体阳性#

Cancer Med：二氯化镭-223联合激素治疗激素受体阳性骨转移性乳腺癌的II期研究

2021-01-14

mjldent (审核中...)

前往app查看评论内容

#激素受体阳性#

让激素受体阳性乳腺癌患者的选择不再困难

2019-09-06

科室
- - 订阅+
  - 更多科室
工具
服务